Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
TK
Alpha Teknova, Inc. Common Stock
TKNO
Mkt Cap
$381.3M
Volume
347.39K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
TK
TKNO
TK
Alpha Teknova, Inc. Common Stock
TKNO
News
·
All You Need to Know About Alpha Teknova (TKNO) Rating Upgrade to Buy
Mkt Cap
$380.1M
Volume
347.39K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
All You Need to Know About Alpha Teknova (TKNO) Rating Upgrade to Buy
Alpha Teknova (TKNO) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates over the past three months with a 5.2% increase in consensus estimates. The upgrade positions the biopharmaceutical reagent maker in the top 20% of Zacks-covered stocks, suggesting potential near-term stock price appreciation driven by improving business fundamentals.
Zacks Investment Research · Oct 1, 2026
Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies
Teknova and Pluristyx are collaborating to produce and commercialize Pluristyx's PluriFreeze cryopreservation system, which is designed to simplify the scale-up process for companies working to bring allogeneic cell therapies to market.
GlobeNewswire Inc. · Mar 11, 2025
Telegraph Hill Partners buys $15m of Alpha Teknova shares at $1.24 each - Investing.com
Telegraph Hill Partners, a major shareholder in Alpha Teknova, Inc., has increased its stake in the company through a private placement, purchasing shares worth approximately $15 million at $1.24 per share. This transaction reflects a positive outlook from Telegraph Hill Partners on Alpha Teknova's future prospects.
Investing.com · Jul 17, 2024
After Plunging -24.59% in 4 Weeks, Here's Why the Trend Might Reverse for Alpha Teknova (TKNO)
Alpha Teknova (TKNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks Investment Research · Jun 24, 2024
Alpha Teknova (TKNO) Upgraded to Buy: What Does It Mean for the Stock?
Alpha Teknova (TKNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research · Jun 6, 2024
Teknova Reports First Quarter 2024 Financial Results
First quarter 2024 total revenue was $9.3 million, up 2% from prior yearLaunch of Build-Tek™ Custom ConfiguratorCompany reaffirms 2024 revenue guidance of $35-38 million
GlobeNewswire Inc. · May 13, 2024
Teknova Launches Proprietary Build-Tek™ Solutions Custom Configurator and Latest AAV-Tek™ Product to Further Accelerate Novel Therapy Development
First-of-its-kind custom configurator – available today – gives scientists access to high quality, customizable buffers in small volumes for use in early-stage experiments, all with exceptionally short turnaround times
GlobeNewswire Inc. · May 7, 2024
Teknova to Report First Quarter 2024 Financial Results on May 13, 2024
HOLLISTER, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, following the close of market.
GlobeNewswire Inc. · Apr 29, 2024
Down -28.04% in 4 Weeks, Here's Why Alpha Teknova (TKNO) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Alpha Teknova (TKNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks Investment Research · Apr 24, 2024
Teknova Reports Fourth Quarter and Full Year 2023 Financial Results
Full year 2023 total revenue was $36.7 million, down 11% year-over-yearAchieved 36% annual growth in the number of Clinical Solutions customers in 2023Company provides 2024 revenue guidance of $35-38 million
GlobeNewswire Inc. · Mar 11, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
TK
TKNO
Alpha Teknova, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
TKNO
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any TKNO yet.
Related Tickers
Earnings